Trials / Completed
CompletedNCT00282217
Study Evaluating Sirolimus in the Treatment of Kidney Transplant
Sirolimus in the Treatment of Histological Defined Chronic Allograft Nephropathy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to test whether withdrawal of calcineurin inhibitors, followed by treatment with sirolimus, may improve renal function in renal transplant recipients with chronic allograft nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sirolimus |
Timeline
- Start date
- 2006-08-01
- First posted
- 2006-01-25
- Last updated
- 2007-03-22
Locations
13 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00282217. Inclusion in this directory is not an endorsement.